



Nicox launches Xailin Gel, an innovative “preservative-free in the eye” dry eye lubricant

October 14, 2014.

Sophia Antipolis, France.

Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced the launch in Europe of Xailin Gel, an innovative multidose carbomer gel lubricant (medical device) that becomes preservative-free in the eye. Once Xailin Gel is in contact with the eye surface, the substance released by the preservative is converted to water and oxygen by ocular enzymes, making Xailin Gel ‘preservative-free in the eye’. Xailin Gel follows Xailin Night and Xailin Fresh as the third medical device to be introduced in the Xailin™ range of dry eye lubricants.

Philippe Masquida, Executive Vice-President, Managing Director of European & International Operations of Nicox Pharma, commented: *“We are proud to launch Xailin Gel, our third Xailin product, offering to patients a new option which is less likely to have side effects linked to preservatives contained in most eye drops. Our innovative ‘preservative-free in the eye’ formulation enables patients to benefit from a convenient multidose presentation. We are already working on the launch of additional ‘preservative-free in the eye’ products by the end of the year to complete the Xailin range.”*

Xailin™ is a proprietary brand under which Nicox is commercializing a range of quality products for dry eye which are either preservative-free or preservative-free in the eye. Xailin Gel follows Xailin Night, a multi-dose preservative-free lubricating ointment for night-time relief of dry eye sensations, and Xailin Fresh, a unit-dose preservative-free lubricant that alleviates and soothes dry eye sensations, which were launched in early 2014. Other ocular lubricants are planned to be launched as part of the Xailin range by the end of 2014.

Nicox has established a direct commercial presence in the five major European markets, through the recruitment of specialist sales teams in the UK, Spain and Germany and through the acquisitions of Eupharmed in Italy and Doliage in France. In addition, partnerships have been established with third parties for the distribution of Nicox’s products in Switzerland, Turkey, Benelux, Poland, South Africa, Australia and New Zealand.



About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company's commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox's key proprietary asset in ophthalmology is VESNEO (latanoprostene bunod), a novel compound based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.

Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit www.nicox.com.

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the "Document de référence, rapport financier annuel et rapport de gestion 2013" filed with the French Autorité des Marchés Financiers (AMF) on April 2nd, 2014, in the "Rapport semestriel financier et d'activité au 30 juin 2014" and in the 5th chapter of the "Actualisation du Document de Référence 2013" filed on September 30, 2014 (D. 14-0271-A01), available on Nicox's website (www.nicox.com).



Contacts

Nicox

Gavin Spencer | Executive Vice President Corporate Development
Tel +33 (0)4 97 24 53 00 | communications@nicox.com

Media Relations

United Kingdom

Jonathan Birt
M +44 7860 361 746 | jonathan.birt@gmail.com

France

Caroline Courme | Communication Manager
Tel +33 (0)4 97 24 53 43 | courme@nicox.com